Abstract | BACKGROUND: METHODS: As part of a randomized phase II trial, 257 patients received either doxorubicin- cyclophosphamide (AC) or doxorubicin- pemetrexed (AP) followed by docetaxel (Doc; Taxotere) as NCT for T2-4/N0-2/M0 PBC. FGFR4 genotype analyzed on germline DNA was correlated with clinicopathologic variables, clinical response, and pathological complete response (pCR) using univariate and multivariate analyses. RESULTS: Only axillary lymph node status was associated with FGFR4 Arg388 [odds ratio (OR) 1.82, P = 0.03]. Joint analysis of both treatment arms revealed a correlation of FGFR4 Arg388 with clinical response (OR 2.14, P = 0.03) but not with pCR. In the AC-Doc arm, however, FGFR4 Arg388 was a strong predictor of pCR in the multivariate analysis (OR 3.79, P = 0.03). A significant interaction between FGFR4 genotype and treatment (P = 0.01) was found, indicating a therapy-specific effect. CONCLUSION: We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC.
|
Authors | F Marmé, W Werft, A Benner, B Burwinkel, P Sinn, C Sohn, P Lichter, M Hahn, A Schneeweiss |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 21
Issue 8
Pg. 1636-1642
(Aug 2010)
ISSN: 1569-8041 [Electronic] England |
PMID | 20147743
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- DNA Primers
- Arginine
- FGFR4 protein, human
- Receptor, Fibroblast Growth Factor, Type 4
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Arginine
(chemistry, genetics)
- Base Sequence
- Breast Neoplasms
(drug therapy, genetics, pathology)
- Chemotherapy, Adjuvant
- DNA Primers
- Female
- Genotype
- Humans
- Immunohistochemistry
- Middle Aged
- Prognosis
- Receptor, Fibroblast Growth Factor, Type 4
(chemistry, genetics)
- Remission Induction
|